Alkermes (ALKS) Depreciation & Amortization (CF) (2011 - 2026)
Alkermes' (ALKS) quarterly Depreciation & Amortization (CF) came in at $30.3 million in Q2 2026, up 287.26% year-over-year from $7.8 million in Q2 2025, and up 55.83% quarter-over-quarter from $19.4 million in Q1 2026.
Analysis
Alkermes (ALKS) Depreciation & Amortization (CF) (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $30.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 287.26% year-over-year to $30.3 million in Q2 2026; TTM through Jun 2026 was $61.6 million, a 112.1% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, down 4.79% from the prior year.
- Depreciation & Amortization (CF) was $30.3 million for Q2 2026 at Alkermes, up from $19.4 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $30.3 million in Q2 2026 and troughed at $3.8 million in Q4 2025.
- A 5-year average of $14.3 million and a median of $18.6 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) tumbled 64.98% in 2024 and surged 287.26% in 2026, its largest moves.
- Over 5 years, Depreciation & Amortization (CF) stood at $19.7 million in 2022, then decreased by 5.77% to $18.5 million in 2023, then slumped by 63.07% to $6.8 million in 2024, then tumbled by 43.83% to $3.8 million in 2025, then jumped by 687.21% to $30.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $30.3 million (Q2 2026), $19.4 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.93 Bn | 625.17 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 443.06 Bn | 436.49 Bn | 12.70 Bn | - |
| 3 | Merck | 365.76 Bn | 358.62 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.47 Bn | 258.78 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 1.62 Bn |
| 6 | Sanofi | 52.36 Bn | 44.98 Bn | 10.79 Bn | 3.97 Bn |
| 7 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | 26.48 Mn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn | 24.20 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 30.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.28 Mn |
| Mar 31, 2026 | 19.43 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | 6.85 Mn |
| Sep 30, 2024 | 6.97 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Mar 31, 2024 | 8.06 Mn |
| Dec 31, 2023 | 18.54 Mn |
| Sep 30, 2023 | 18.66 Mn |
| Jun 30, 2023 | 19.01 Mn |
| Mar 31, 2023 | 18.71 Mn |
| Dec 31, 2022 | 19.68 Mn |
| Sep 30, 2022 | 19.60 Mn |
| Jun 30, 2022 | 19.39 Mn |
| Mar 31, 2022 | 19.20 Mn |
| Dec 31, 2021 | 21.14 Mn |
| Sep 30, 2021 | 19.39 Mn |